Delfi launches its blood test to screen for lung cancer – and reveals challenges for liquid biopsies
Taking aim at a major killer, the well-funded startup Delfi Diagnostics launches a blood test to screen for lung cancer.
Related Articles
Takeda is fourth big company to leave BIO since December
Takeda Pharmaceuticals has left BIO, the fourth departure of a major member since December, the company confirmed.
What we know about traces of H5N1 bird flu found in pasteurized milk
Genetic evidence of H5N1 bird flu virus has been found in grocery store milk, according to the FDA. In this video, STAT explains what is…
Biogen’s Alzheimer’s drug launch on ‘steady pace’ as logistical hurdles recede
Biogen on Wednesday reported first-quarter earnings that beat Wall Street expectations largely on reduced expenses.
Biosimilars haven’t always yielded lower out-of-pocket costs for patients, study finds
The authors of a new study argue the heralded arrival of biosimilars failed to fully deliver on their promise.
Déjà WTO: The WHO’s pandemic agreement shouldn’t water down intellectual property obligations
As the Covid-19 experience showed, trying to address IP during a pandemic doesn’t work, and voluntary sharing of IP during a pandemic doesn’t work.
Biosimilars haven’t always yielded lower out-of-pocket costs for patients, study finds
The authors of a new study argue the heralded arrival of biosimilars failed to fully deliver on their promise.
New studies suggest GLP-1 health care costs have only begun to climb
Costs for the U.S. health care system and the federal government will climb thanks to weight loss drugs, two new reports show.
STAT readers respond to First Opinion essays on site-neutral payments, free medical school tuition, and more
It takes great minds with a lot of heart to find a cure for diseases like Duchenne muscular dystrophy.
Massive amounts of H5N1 vaccine would be needed if there’s a bird flu pandemic. Can we make enough?
The first signs that H5N1 avian flu was starting to spread from person to person would trigger a race to produce massive amounts of vaccine.
Anticompetitive hospital mergers skate by due to FTC’s shallow resources
The agency simply doesn’t have enough resources to challenge but 1% of hospital mergers, so they continue to result in less competition and higher prices.